Disease Elimination Program, Burnet Institute, Melbourne, Australia.
School of Population Health and Preventive Medicine, Monash University, Melbourne, Australia.
BMC Health Serv Res. 2024 Jan 16;24(1):80. doi: 10.1186/s12913-023-10456-0.
Globally, 56.8 million people are living with hepatitis C and over three-quarters of those reside in low and middle-income countries (LMICs). Barriers and enablers to hepatitis C care among people who inject drugs in high-income countries are well documented. However, there is scant literature describing the patient experience in LMICs. Understanding the barriers and enablers to care from the patient perspective is important to inform service refinements to improve accessibility and acceptability of hepatitis C care.
We conducted a qualitative evaluation of the patient experience of accessing the national hepatitis C program at eight hospital sites in Myanmar. Semi-structured interviews were conducted with four to five participants per site. Interview data were analysed thematically, with deductive codes from Levesque et al.'s (2013) Framework on patient-centred access to healthcare.
Across the eight sites, 38 participants who had completed treatment were interviewed. Barriers to accessing care were mostly related to attending for care and included travel time and costs, multiple appointments, and wait times. Some participants described how they did not receive adequate information on hepatitis C, particularly its transmission routes, and on the level of cirrhosis of their liver and what they were required to do after treatment (i.e. reduce alcohol consumption, liver cirrhosis monitoring). Many participants commented that they had few or no opportunities to ask questions. Provision of treatment at no cost was essential to accessibility, and gratitude for free treatment led to high acceptability of care, even when accessing care was inconvenient.
These findings highlight the importance of streamlining and decentralising health services, adequate human resourcing and training, and affordable treatment in maximising the accessibility and acceptability of hepatitis C care in LMICs. Findings from this work will inform future service delivery refinements for national program and other decentralised programs to improve accessibility and acceptability of hepatitis C care in Myanmar.
全球有 5680 万人患有丙型肝炎,其中超过四分之三的人居住在中低收入国家(LMICs)。在高收入国家,注射毒品者接受丙型肝炎护理的障碍和促进因素已有大量文献记载。然而,关于中低收入国家患者体验的文献却很少。从患者的角度了解护理的障碍和促进因素对于改进服务以提高丙型肝炎护理的可及性和可接受性非常重要。
我们对缅甸 8 家医院的国家丙型肝炎计划的患者体验进行了定性评估。在每个地点对 4 到 5 名参与者进行了半结构化访谈。对访谈数据进行了主题分析,使用了 Levesque 等人(2013 年)的《以患者为中心获得医疗保健框架》中的衍生代码。
在这 8 个地点,共采访了 38 名完成治疗的参与者。获得护理的障碍主要与护理就诊有关,包括旅行时间和费用、多次预约和等待时间。一些参与者描述了他们没有收到足够的关于丙型肝炎的信息,特别是它的传播途径,以及他们的肝脏肝硬化程度以及治疗后需要做什么(即减少饮酒量、肝硬化监测)。许多参与者表示,他们几乎没有或没有机会提问。免费提供治疗对可及性至关重要,对免费治疗的感激之情导致对护理的高接受度,即使在获得护理不方便的情况下也是如此。
这些发现强调了简化和分散卫生服务、充足的人力资源和培训以及负担得起的治疗在最大限度地提高中低收入国家丙型肝炎护理的可及性和可接受性方面的重要性。这项工作的结果将为国家计划和其他分散计划的未来服务提供改进提供信息,以提高缅甸丙型肝炎护理的可及性和可接受性。